Santen Pharmaceutical Co., Ltd. (SNPHY)

Market Cap	3.18B +0.7%
Revenue (ttm)	1.84B -4.6%
Net Income	195.16M +11.3%
EPS	0.59 +18.7%
Shares Out	n/a
PE Ratio	16.32
Forward PE	n/a
Dividend	0.25 (2.39%)
Ex-Dividend Date	Mar 30, 2026

Volume	354
Average Volume	28,744
Open	11.54
Previous Close	10.34
Day's Range	11.54 - 11.54
52-Week Range	9.22 - 12.68
Beta	0.23
RSI	44.29
Earnings Date	May 12, 2026

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNPHY

Financial Performance

In fiscal year 2026, Santen Pharmaceutical's revenue was 291.62 billion, a decrease of -2.79% compared to the previous year's 300.00 billion. Earnings were 37.37 billion, an increase of 3.10%.

Financial numbers in JPY